FDA clears Viatronix 3D cardiac application

Viatronix, a developer of 3D imaging software, has received FDA’s 510(k) market clearance for its V3D-Cardiac module.

The V3D-Cardiac application combines left ventricle and coronary analysis functions into a single user-friendly module, allowing both functions are analyzed in a single application according to the Stony Brook, N.Y.-based company.

Viatronix said that the V3D-Cardiac module has real-time analysis of cardiac CTC data; integration with PACS workstations; one-click segmentation of the heart; one-click selection and analysis of coronary vessels; multi-phase cardiac function review; computation of ejection fraction; coronary vessel endoluminal fly-through; one-click segmentation of the left ventricle and automatic determination of long axis; and customizable reporting is integrated into the workflow.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.